PriceTargets.com logo

Ventyx Biosciences - VTYX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 434.76%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.87 As of 11/15/2024 01:00 AM ET
▼ -0.1 (-5.08%)

This chart shows the closing price for VTYX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ventyx Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VTYX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VTYX

Analyst Price Target is $10.00
▲ +434.76% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Ventyx Biosciences in the last 3 months. The average price target is $10.00, with a high forecast of $14.00 and a low forecast of $6.00. The average price target represents a 434.76% upside from the last price of $1.87.

This chart shows the closing price for VTYX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in Ventyx Biosciences. This rating has held steady since February 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$6.00 ➝ $6.00
11/8/2024OppenheimerReiterated RatingOutperform ➝ Outperform$10.00 ➝ $9.00
10/15/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$6.00 ➝ $6.00
9/23/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$6.00 ➝ $6.00
8/12/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$16.00 ➝ $11.00
8/12/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$15.00 ➝ $14.00
7/30/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$6.00 ➝ $6.00
6/13/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$6.00 ➝ $6.00
6/6/2024OppenheimerLower TargetOutperform ➝ Outperform$12.00 ➝ $10.00
6/6/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$6.00 ➝ $6.00
3/13/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$16.00 ➝ $15.00
3/12/2024OppenheimerUpgradeMarket Perform ➝ Outperform$12.00
3/12/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$7.00 ➝ $16.00
2/28/2024Lifesci CapitalUpgradeMarket Perform ➝ Outperform
2/21/2024OppenheimerReiterated RatingMarket Perform
11/10/2023Evercore ISIReiterated RatingOutperform ➝ In-Line$43.00 ➝ $5.00
11/7/2023Lifesci CapitalDowngradeOutperform ➝ Market Perform
11/7/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$46.00 ➝ $6.00
11/7/2023OppenheimerDowngradeOutperform ➝ Market Perform
11/7/2023HC WainwrightDowngradeBuy ➝ Neutral
11/7/2023Stifel NicolausDowngradeBuy ➝ Hold$6.00
11/7/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$77.00 ➝ $8.00
10/10/2023Stifel NicolausReiterated RatingBuy ➝ Buy$56.00
10/10/2023Evercore ISILower Target$65.00 ➝ $47.00
10/10/2023OppenheimerLower Target$57.00 ➝ $56.00
10/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$52.00
8/29/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$45.00 ➝ $46.00
8/11/2023Credit Suisse GroupLower TargetOutperform ➝ Outperform$63.00 ➝ $62.00
8/11/2023HC WainwrightLower TargetBuy ➝ Buy$54.00 ➝ $52.00
8/11/2023OppenheimerLower Target$62.00 ➝ $57.00
6/14/2023Credit Suisse GroupInitiated CoverageOutperform$63.00
5/12/2023500.comReiterated RatingReiterates
3/24/2023OppenheimerLower TargetOutperform$65.00 ➝ $62.00
3/20/2023Wells Fargo & CompanyInitiated CoverageOverweight$77.00
3/20/2023OppenheimerBoost Target$60.00 ➝ $65.00
1/31/2023Canaccord Genuity GroupBoost TargetBuy$35.00 ➝ $54.00
1/27/2023OppenheimerBoost TargetOutperform$55.00 ➝ $60.00
1/26/2023Evercore ISIBoost Target$50.00 ➝ $65.00
12/19/2022The Goldman Sachs GroupInitiated CoverageBuy$50.00
11/17/2022Morgan StanleyInitiated CoverageOverweight$45.00
9/16/2022Stifel NicolausBoost TargetBuy$45.00 ➝ $53.00
9/13/2022HC WainwrightBoost TargetBuy$36.00 ➝ $50.00
9/12/2022OppenheimerBoost TargetOutperform$40.00 ➝ $65.00
9/6/2022Stifel NicolausInitiated CoverageBuy$45.00
9/1/2022HC WainwrightInitiated CoverageBuy$36.00
8/17/2022Canaccord Genuity GroupBoost Target$30.00 ➝ $35.00
8/16/2022Credit Suisse GroupBoost TargetOutperform$53.00 ➝ $63.00
8/16/2022OppenheimerBoost TargetOutperform$30.00 ➝ $40.00
5/9/2022Credit Suisse GroupInitiated CoverageOutperform$53.00
3/31/2022Canaccord Genuity GroupInitiated CoverageBuy
2/1/2022OppenheimerInitiated CoverageOutperform$30.00
11/15/2021Lifesci CapitalReiterated RatingOutperform
11/15/2021Evercore ISIInitiated CoverageOutperform$50.00
11/15/2021Jefferies Financial GroupInitiated CoverageBuy$30.00
11/15/2021Piper SandlerInitiated CoverageOverweight$50.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 39 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 1 very positive mentions
  • 27 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Ventyx Biosciences logo
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Read More

Today's Range

Now: $1.87
Low: $1.87
High: $2.00

50 Day Range

MA: $2.23
Low: $1.87
High: $2.57

52 Week Range

Now: $1.87
Low: $1.79
High: $11.48

Volume

1,297,988 shs

Average Volume

938,125 shs

Market Capitalization

$132.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Ventyx Biosciences?

The following Wall Street analysts have issued reports on Ventyx Biosciences in the last year: Canaccord Genuity Group Inc., HC Wainwright, Lifesci Capital, Oppenheimer Holdings Inc., and Wells Fargo & Company.
View the latest analyst ratings for VTYX.

What is the current price target for Ventyx Biosciences?

0 Wall Street analysts have set twelve-month price targets for Ventyx Biosciences in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 434.8%. Canaccord Genuity Group Inc. has the highest price target set, predicting VTYX will reach $14.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for Ventyx Biosciences in the next year.
View the latest price targets for VTYX.

What is the current consensus analyst rating for Ventyx Biosciences?

Ventyx Biosciences currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for VTYX.

What other companies compete with Ventyx Biosciences?

Other companies that are similar to Ventyx Biosciences include Y-mAbs Therapeutics, Acelyrin, Larimar Therapeutics, Mereo BioPharma Group and VectivBio. Learn More about companies similar to Ventyx Biosciences.

How do I contact Ventyx Biosciences' investor relations team?

The company's listed phone number is 760-593-4832 and its investor relations email address is [email protected]. The official website for Ventyx Biosciences is www.ventyxbio.com. Learn More about contacing Ventyx Biosciences investor relations.